<DOC>
	<DOCNO>NCT01378104</DOCNO>
	<brief_summary>1 . Randomized control multicenter study 2 . The response reduce dose peginterferon alfa-2a Koreans chronic hepatitis C genotype 1 3 . IL28B polymorphism Koreans CHC</brief_summary>
	<brief_title>100 % VS 80 % Of Pegasys In Koreans With Chronic Hepatitis C ( CHC )</brief_title>
	<detailed_description>The virologic response Koreans combination therapy chronic hepatitis C similar non-Asians ; however , dose modification occur frequently Koreans . -When evaluated rate peginterferon α-2a ribavirin dose modification effect virologic response Koreans , suggest use least 80 % peginterferon α-2a dose Koreans maintain SVR also reduce drug side effect entire treatment period lower dose ribavirin may efficacious standard dose ( Korean J Intern Med 2009 ; 24:203-211 ) . So investigate whether group 80 % use dosage peginterferon alfa-2a show inferior response rather 100 % use dosage group minimize adverse event . There recently report Koreans favorable IL28B SNP CHC treatment . -We investigate IL28B polymorphism Koreans CHC result effect SVR depend dosage peginterferon alfa 2a</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>chronic hepatitis C ( anti HCV+ , HCV RNA + ) Genotype 1 18 yearold Pregnancy test negative woman childbearing age pregnant woman breast feed woman systemic chemotherapy steroid therapy 6 month trial Coinfection HAV , HBV , HIV Other liver disease hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxic hepatitis Hepatocellular carcinoma Evidence decompensation variceal bleeding , ascites , encephalopathy ANC le 1500 , platelet le 90k Cr 1.5 UNL Severe psychiatric problem Poorly control thyroid disease Severe retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>reduce dose peginterferon</keyword>
	<keyword>chronic hepatitis c</keyword>
	<keyword>Koreans</keyword>
	<keyword>IL28B polymorphism</keyword>
</DOC>